Mr. James Passin reports

BIOVAXYS ANNOUNCES PHASE I/II PESCO TRIAL ABSTRACT ACCEPTED FOR PRESENTATION AT THE 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

Biovaxys Technology Corp. has received acceptance of an abstract related to the PESCO study, an investigator-initiated, open-label, non-randomized phase 1B/2 trial to evaluate the safety and efficacy of combination of Biovaxys's MVP-S with pembrolizumab (Keytruda) and cyclophosphamide in patients with recurrent epithelial ovarian cancer for presentation at the American Society of Clinical Oncology (ASCO) annual meeting, taking place in Chicago, May 29 to June 6, 2026.

With over 44,000 expected attendees, including oncologists, researchers and pharmaceutical professionals, the ASCO annual meeting is a top-tier global oncology conference, and is recognized as one of the most significant, high-visibility events for clinical trials, research and oncology innovation. All accepted ASCO abstracts are published online as a supplement to the Journal of Clinical Oncology (JCO).

MVP-S is Biovaxys' investigational immunotherapeutic vaccine that uses its lipid-based DPX delivery platform to stimulate T-cell immune response to survivin epitopes restricted by 5 HLA class I haplotypes. MVP-S is in clinical development for ovarian, bladder and breast cancer, and for relapsed/refractory diffuse large B-cell lymphoma.

Led by principal investigator Amit Oza, MD, head of the division of medical oncology and hematology, and medical director of University Health Network, cancer clinical research unit, at Princess Margaret Cancer Centre (PMCC), director of the Drug Development Program at the PMCC, and professor of medicine, University of Toronto, the abstract is entitled "Vaccine-induced immune responses, HLA genotyping and molecular profiling in patients with metastatic ovarian cancer (the PESCO trial)."

The PESCO study was sponsored by University Health Network, with support from the Princess Margaret Cancer Centre, The Ontario Institute for Cancer Research, and Merck Sharp & Dohme.

Details are as follows:

Abstract title:  Vaccine-induced immune responses, HLA genotyping and molecular profiling in patients with metastatic ovarian cancer (the PESCO trial)

Session type/title:  poster session -- gynecologic cancer

Poster board:  266

Date and time:  June 1, 2026, 9 a.m. 12 p.m. CT

About the Biovaxys DPX platform

The Biovaxys DPX platform is a major innovation in vaccine development that offers a solution to limitations faced by vaccines using other antigen delivery methods. The DPX platform presents antigens to the immune system using a novel non-systemic mechanism of action that does not release active ingredients at the site of the injection, but rather forces an active uptake of immune cells and delivery into the lymphatic nodes. The programming of immune cells happens in vivo and offers a more efficient approach that mimics the natural function of the immune system. This no-release mechanism allows for an active uptake of antigens into immune cells and lymph nodes for a sustained activation of the immune system in which the T-cell flow is sustained over a longer duration than traditional vaccines on the market.

About Maveropepimut-S (MVP-S)

Survivin, a tumour-associated antigen, is highly expressed in ovarian and other cancers but nearly undetectable in normal tissues, making it a promising target for ovarian cancer immunotherapy. Designed to target and eliminate survivin-expressing tumour cells, Biovaxys's maveropepimut-S (MVP-S) is a DPX-based vaccine immunotherapy that induces a cytotoxic T-cell response. DPX is a non-aqueous, non-systemic, lipid-in-oil immune educating antigen delivering platform that is the foundation of Biovaxys's oncology and infectious disease product pipeline. MVP-S is a DPX-based formulation of five peptides derived from survivin, a T helper peptide and an innate immune stimulant, which delivers instruction to the immune system to generate a specific, robust and persistent immune response. MVP-S has been shown to be well tolerated and has demonstrated activation of a targeted and sustained, survivin-specific anti-tumour immune response in multiple cancer indications, such as in Biovaxys's recent phase 1 study of MVP-S with neoadjuvant hormone therapy in HR(+)/HER2(-) stage II to III breast cancer.

About ovarian cancer

Epithelial ovarian cancer (EOC), characterized by a pattern of relapse and progression through successive recurrences, has overall poor survival due to late detection, high heterogenicity and development of resistance, highlighting the urgent need for novel treatment strategies. New advances, such as immune checkpoint inhibitor monotherapy, have demonstrated limited efficacy in treating ovarian cancer. Recent studies with checkpoint inhibitors, such as anti PD-1, with immunotherapeutic cancer vaccines demonstrates the potential to expand antigen-specific T cells and inhibit regulatory T cells (Tregs), thereby enhancing the overall tumour immune response. Additional studies have shown a synergistic effect between checkpoint inhibitors and cancer vaccines, thus positioning these combinations for further exploration, with the optimization of these combinations reliant on selection of the ideal cancer vaccine antigens.

Ovarian cancer is one of the deadliest malignancies in women and remains the leading cause of death from gynecological cancers worldwide. Epithelial ovarian cancer (EOC) is the most common type, accounting for 90 per cent of all ovarian cancer cases, with high-grade serous ovarian cancer (HGSOC) being the most aggressive and recurrent subtype. The standard treatment typically involves tumour-reducing surgery and cytotoxic chemotherapy; however, many patients are unable to tolerate the side effects of these treatments or experience recurrence due to significant drug resistance, which limits the overall clinical benefits.

The global epithelial ovarian cancer market is projected to reach over $7.0-billion (U.S.) by 2033, reflecting robust growth fuelled by innovation and expanding treatment options.

About Biovaxys Technology Corp.

Biovaxys Technology, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform, for treating cancers, infectious disease, antigen desensitization for food allergy and other immunological diseases. Through a differentiated mechanism of action, the DPX platform delivers instruction to the immune system to generate a specific, robust and persistent immune response. The company's clinical stage oncology pipeline includes maveropepimut-S (MVP-S), based on the DPX platform, in phase II clinical development for advanced relapsed-refractory diffuse large B-cell lymphoma and platinum-resistant ovarian cancer, and in phase 1 with neoadjuvant hormone therapy in HR(+)/HER2(-) stage II to III breast cancer. Biovaxys is also developing DPX+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX-RSV for respiratory syncytial virus, DPX+rPA for peanut allergy prophylaxis and an DPX-mRNA formulation for rabies.

Biovaxys common shares are listed on the Canadian Securities Exchange under the stock symbol BIOV, trade on the Frankfurt Bourse (FSE: 5LB0) and in the United States on the OTC Markets (OTCQB: BVAXF).

We seek Safe Harbor.